Natural Health Science News The latest news and top resources on natural health.

Statins – Adverse Effects

Posted April 27, 2017

Lovastatin and hypospermia.

Statin: lovastatin (mevacor)

Adverse effect: hypospermia

Hildebrand, R. D., and T. W. Hepperlen. “Lovastatin and Hypospermia.” [In eng]. Ann Intern Med 112, no. 7 (Apr 01 1990): 549-50.

Rhabdomyolysis and simvastatin.

Statin: simvastatin (Zocor)

Adverse effect: rhabdomyolysis

Deslypere, J. P., and A. Vermeulen. “Rhabdomyolysis and Simvastatin.” [In eng]. Ann Intern Med 114, no. 4 (Feb 15 1991): 342.

SLCO1B1 Polymorphisms and Statin-Induced Myopathy.

Statin: simvastatin

Adverse effect: rhabdomyolysis

Stewart, A. “Slco1b1 Polymorphisms and Statin-Induced Myopathy.” [In eng]. PLoS Curr 5 (Dec 04 2013).

Striated muscle safety of ezetimibe/simvastatin (Vytorin).

Statin: simvastatin

Adverse effect: rhabdomyolysis

Sabia, H., P. Prasad, H. T. Smith, R. R. Stoltz, and P. Rothenberg. “Safety, Tolerability, and Pharmacokinetics of an Extended-Release Formulation of Fluvastatin Administered Once Daily to Patients with Primary Hypercholesterolemia.” [In eng]. J Cardiovasc Pharmacol 37, no. 5 (May 2001): 502-11.

Safety, tolerability, and pharmacokinetics of an extended-release formulation of fluvastatin administered once daily to patients with primary hypercholesterolemia.

Statin: fluvastatin

Adverse effect: diarrhea, headache, and clinically relevant elevations in serum transaminase concentrations

Sabia, H., P. Prasad, H. T. Smith, R. R. Stoltz, and P. Rothenberg. “Safety, Tolerability, and Pharmacokinetics of an Extended-Release Formulation of Fluvastatin Administered Once Daily to Patients with Primary Hypercholesterolemia.” [In eng]. J Cardiovasc Pharmacol 37, no. 5 (May 2001): 502-11.

Statins: hepatotoxicity and monitoring; Statines : quelle hepatotoxicite et quelle surveillance?

Statin: Not cited

Adverse effect: Liver injury

Cadranel, J. F., M. Seddik, S. Loric, and S. Jeanne. “[Statins: Hepatotoxicity and Monitoring].” [In fre]. Presse Med 38, no. 5 (May 2009): 717-25.

Statins and pancreatitis: A systematic review of observational studies and spontaneous case reports.

Statin: Not cited

Adverse effect: pancreatitis

Singh, S., and Y. K. Loke. “Statins and Pancreatitis: A Systematic Review of Observational Studies and Spontaneous Case Reports.” [In eng]. Drug Saf 29, no. 12 (2006): 1123-32.

Rosuvastatin: An independent analysis of risks and benefits.

Statin: rosuvastatin, cerivastatin

Adverse effect: proteinuria, myopathy, rhabdomyolysis

Zipes, D. P., N. J. Zvaifler, R. J. Glassock, S. Gilman, A. Munoz, V. Gogolak, L. Gordis, et al. “Rosuvastatin: An Independent Analysis of Risks and Benefits.” [In eng]. MedGenMed 8, no. 2 (Jun 14 2006): 73.

The withdrawal of Baycol (cerivastatin).

Statin: cerivastatin

Adverse effect: Not cited

Griffin, J. P. “The Withdrawal of Baycol (Cerivastatin).” [In eng]. Adverse Drug React Toxicol Rev 20, no. 4 (Dec 2001): 177-80.

Potential adverse effects of statins on muscle.

Statin: Not cited

Adverse effect: myopathy

Tomlinson, S. S., and K. K. Mangione. “Potential Adverse Effects of Statins on Muscle.” [In eng]. Phys Ther 85, no. 5 (May 2005): 459-65.

Forecasting cholesterol management – End of the statin gold rush?

Statin: Not cited

Adverse effect: Not cited

Crownover, B. K., and F. R. Curtiss. “Forecasting Cholesterol Management–End of the Statin Gold Rush?” [In eng]. J Manag Care Pharm 12, no. 6 (Jul-Aug 2006): 479-85.

Statins in neurological disorders: An overview and update.

Statin: Not cited

Adverse effect: No adverse effects, therapeutic for neurological diseases

Malfitano, A. M., G. Marasco, M. C. Proto, C. Laezza, P. Gazzerro, and M. Bifulco. “Statins in Neurological Disorders: An Overview and Update.” [In eng]. Pharmacol Res 88 (Oct 2014): 74-83.

Cutaneous adverse effects of statins.

Statin: Not cited

Adverse effect: cutaneous effects

Schmutz, J. L., A. Barbaud, and P. Trechot. “[Cutaneous Adverse Effects of Statins].” [In fre]. Ann Dermatol Venereol 135, no. 3 (Mar 2008): 253-4.

Statins and elevated liver tests: What’s the fuss?

Statin: Not cited

Adverse effect: Not cited

Onusko, E. “Statins and Elevated Liver Tests: What’s the Fuss?” [In eng]. J Fam Pract 57, no. 7 (Jul 2008): 449-52.

Safety of statins: Effects on muscle and the liver.

Statin: Not cited

Adverse effect: muscle and liver related Aes

Vasudevan, A. R., Y. S. Hamirani, and P. H. Jones. “Safety of Statins: Effects on Muscle and the Liver.” [In eng]. Cleve Clin J Med 72, no. 11 (Nov 2005): 990-3, 96-1001.

A neuromuscular approach to statin-related myotoxicity.

Statin: Not cited

Adverse effect: muscle related AEs

Baker, S. K., and I. A. Samjoo. “A Neuromuscular Approach to Statin-Related Myotoxicity.” [In eng]. Can J Neurol Sci 35, no. 1 (Mar 2008): 8-21.

FDA adverse event reports on statin-associated rhabdomyolysis.

Statin: simvastatin; cerivastatin; atorvastatin; pravastatin; lovastatin; and fluvastatin

Adverse effect: rhabdomyolysis

Omar, M. A., and J. P. Wilson. “Fda Adverse Event Reports on Statin-Associated Rhabdomyolysis.” [In eng]. Ann Pharmacother 36, no. 2 (Feb 2002): 288-95.

Statin Safety: An Appraisal from the Adverse Event Reporting System.

Statin: rosuvastatin

Adverse effect: rhabdomyolysis, renal failure

Davidson, M. H., J. A. Clark, L. M. Glass, and A. Kanumalla. “Statin Safety: An Appraisal from the Adverse Event Reporting System.” [In eng]. Am J Cardiol 97, no. 8A (Apr 17 2006): 32C-43C.